摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidine | 153108-88-4

中文名称
——
中文别名
——
英文名称
(7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidine
英文别名
(7R,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-<(E)-(R)-2-methylhexylidene>octahydroindolizine;(7R,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-((E)-(R)-2-methylhexylidene)octahydroindolizine;(6E,7R,8R,8aS)-8-methyl-6-[(2R)-2-methylhexylidene]-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol
(7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidine化学式
CAS
153108-88-4
化学式
C23H35NO2
mdl
——
分子量
357.536
InChiKey
OQYDSVGYSHAEGF-HZGJPHOCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    26
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    32.7
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidinelithium 作用下, 以 四氢呋喃 为溶剂, 以88%的产率得到(+)-allopumiliotoxin 267 A
    参考文献:
    名称:
    双环杂环的镍催化制备:(+)-别孔雀石毒素 267A、(+)-别孔雀石毒素 339A 和 (+)-别孔雀石毒素 339B 的全合成
    摘要:
    开发了一种涉及 Ni(COD)2/PBu3 催化剂体系的 ynals 还原环化生产烯丙醇的新方法。三乙基硅烷介导的程序允许制备...
    DOI:
    10.1021/ja001440t
  • 作为产物:
    描述:
    (R)-1,1-dibromo-3-methylheptene 在 甲醇正丁基锂聚合甲醛 、 camphor-10-sulfonic acid 、 仲丁基锂silver nitrate 、 sodium iodide 作用下, 以 乙醇 为溶剂, 反应 34.75h, 生成 (7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidine
    参考文献:
    名称:
    Allopumiliotoxins 267A、323B'和339A的对映选择性总合成 碘化物促进的亚胺鎓-炔环化反应在形成别藻毒素 A 生物碱中的应用
    摘要:
    描述了一种用于 allopumiliotoxin A 生物碱全合成的简洁、立体控制的策略。Enantiopure (+)-allopumiliotoxin 267A (3) 的第二代全合成在 10 个步骤中完成,来自市售的恶唑烷酮前体醇 32 和 17 个步骤的总产率为 11%,N-[(3) 的总产率为 4%。苄氧基)羰基]-1-脯氨酸。(+)-allopumiliotoxin 323B' (4) 的首次合成严格证实了 4 的完整立体结构,并确定从 dendrobatid 青蛙中分离出的主要 C(15) 差向异构体具有 15S 配置。4的全合成分5步实现,炔烃39和醛20的总收率为17%;从 (S)-2-methyl-1-penten-3-ol 合成 13 步,总产率为 6%,17 步和 3。
    DOI:
    10.1021/ja961640y
点击查看最新优质反应信息

文献信息

  • Aoyagi, Sakae; Wang, Tzu-Chueh; Kibayashi, Chihiro, Journal of the American Chemical Society, 1993, vol. 115, # 24, p. 11393 - 11409
    作者:Aoyagi, Sakae、Wang, Tzu-Chueh、Kibayashi, Chihiro
    DOI:——
    日期:——
  • Nickel Catalysis in the Stereoselective Preparation of Quinolizidine, Pyrrolizidine, and Indolizidine Alkaloids:  Total Synthesis of (+)-Allopumiliotoxin 267A
    作者:Xiao-Qing Tang、John Montgomery
    DOI:10.1021/ja990997+
    日期:1999.6.1
  • Enantioselective Total Syntheses of Allopumiliotoxins 267A, 323B‘, and 339A. Application of Iodide-Promoted Iminium Ion−Alkyne Cyclizations for Forming Allopumiliotoxin A Alkaloids
    作者:Christian Caderas、Renee Lett、Larry E. Overman、Michael H. Rabinowitz、Leslie A. Robinson、Matthew J. Sharp、Jeffery Zablocki
    DOI:10.1021/ja961640y
    日期:1996.1.1
    The first synthesis of (+)-allopumiliotoxin 323B‘ (4) rigorously confirms the complete stereostructure of 4 and establishes that the major C(15) epimer isolated from dendrobatid frogs has the 15S configuration. The total synthesis of 4 was realized in 5 steps and 17% overall yield from alkyne 39 and aldehyde 20; the synthesis proceeded in 13 steps and 6% overall yield from (S)-2-methyl-1-penten-3-ol and
    描述了一种用于 allopumiliotoxin A 生物碱全合成的简洁、立体控制的策略。Enantiopure (+)-allopumiliotoxin 267A (3) 的第二代全合成在 10 个步骤中完成,来自市售的恶唑烷酮前体醇 32 和 17 个步骤的总产率为 11%,N-[(3) 的总产率为 4%。苄氧基)羰基]-1-脯氨酸。(+)-allopumiliotoxin 323B' (4) 的首次合成严格证实了 4 的完整立体结构,并确定从 dendrobatid 青蛙中分离出的主要 C(15) 差向异构体具有 15S 配置。4的全合成分5步实现,炔烃39和醛20的总收率为17%;从 (S)-2-methyl-1-penten-3-ol 合成 13 步,总产率为 6%,17 步和 3。
  • Nickel-Catalyzed Preparation of Bicyclic Heterocycles:  Total Synthesis of (+)-Allopumiliotoxin 267A, (+)-Allopumiliotoxin 339A, and (+)-Allopumiliotoxin 339B
    作者:Xiao-Qing Tang、John Montgomery
    DOI:10.1021/ja001440t
    日期:2000.7.26
    A new method for the reductive cyclization of ynals involving a Ni(COD)2/PBu3 catalyst system to produce allylic alcohols was developed. The triethylsilane-mediated procedure allows preparation of ...
    开发了一种涉及 Ni(COD)2/PBu3 催化剂体系的 ynals 还原环化生产烯丙醇的新方法。三乙基硅烷介导的程序允许制备...
查看更多

同类化合物

(6E,7R,8R,8aS)-6-[(4E,6S)-6-羟基-2,5-二甲基辛-4-烯-1-亚基]-8-甲基八氢中氮茚-7,8-二醇 pumiliotoxin B pumiliotoxin B (8R,8αS)-8-hydroxy-8-methyl-6-((Z)-2(R)-methyl-hexylidene)octahydroindolizin-7-one erythro pumiliotoxin PTX-B (6Z,8S,8aS)-6-[(2R,4E,6S)-6-(benzyloxy)-2,5-dimethyl-4-octenylidene]-8-{[tert-butyl(dimethyl)silyl]oxy}-8-methyloctahydroindolizine (6Z,8S)-6-[(E,6S)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol (8R,8aS,6E)-8-Hydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizin-7-done (8R,8aS)-8-hydroxy-6-[(E,2R,6S)-1-hydroxy-2,5-dimethyl-6-(phenylmethoxymethoxy)oct-4-enyl]-8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-one (+)-Allopumiliotoxin 323B' Pumiliotoxin 237A (1R,2R,9aS)-1-(benzyloxy)-2-hydroxy-3(E)-isobutylidene-1-methyloctahydroquinolizine (7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidine (+)-allopumiliotoxin 267 A (+)-Pumiliotoxin 251D (3E)-(5S,6S)-5-hydroxy-3-[(R)-2-methylhexylidene]-5-methylazabicyclo[4.3.0]nonan-2-one (8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone (8S,8aS)-8-hydroxy-8-methyl-(6Z)-<(2R,4E,6S)-6-(benzyloxy)-2,5-dimethyl-4-octenylidene>octahydroindolizidine (+)-(15S)-pumiliotoxin A (+)-allopumiliotoxin 339A (6E,7S,8R,8aS)-8-methyl-6-[(E,2R)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]hex-4-enylidene]-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (+)-allopumiliotoxin 339 B (7R,8R,8aS)-8-(benzyloxy)-7-hydroxy-6(Z)-<6(R),7(R)-(isopropylidenedioxy)-2(R),5-dimethyl-4(E)-octenylidene>-8-methyloctahydroindolizine (+)-homopumiliotoxin 223G (6Z)-8-methyl-6-(2-methylhexylidene)-1,2,3,5,7,8a-hexahydroindolizine-7,8-diol (7R,8R,8aS,E)-6-((2R,6R,7R,E)-6,7-Dihydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol (8S,8aS)-6-[2,2-Dimethyl-hex-(Z)-ylidene]-8-methyl-octahydro-indolizin-8-ol (R,4E,8E)-8-((7R,8R,8aS)-7,8-Dihydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-4,7-dimethyloct-4-en-3-one (4E,7R,8Z)-8-((1S,9aS)-1-Hydroxy-1-methyltetrahydro-1H-quinolizin-3(2H,4H,6H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol (1S,9aS,Z)-3-((2R,E)-7-Hydroxy-2,5-dimethyloct-4-en-1-ylidene)-1-methyloctahydro-1H-quinolizin-1-ol (1S,9aS,Z)-3-((2R,E)-6-Hydroxy-2,5-dimethylnon-4-en-1-ylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-6-((R,4E,6E)-2,5-Dimethylocta-4,6-dien-1-ylidene)-8-methyloctahydroindolizin-8-ol (8S,Z)-6-((2R,E)-6-Hydroxy-2,5-dimethylhept-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol (R,Z)-6-((8S,8aS)-8-Hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-5-methylhexan-2-one (8S,8aS,Z)-6-((2R)-4-Hydroxy-2-methylpentylidene)-8-methyloctahydroindolizin-8-ol (1S,9aS,Z)-3-((S)-3-Hydroxy-2-methylpropylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-8-Methyl-6-((R)-2-methylpentylidene)octahydroindolizin-8-ol (6E)-8-methyl-6-(2-methylhexylidene)-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (6Z)-6-[(E)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol (8S,8aS,Z)-6-((2R)-5-Hydroxy-2-methylhexylidene)-8-methyloctahydroindolizin-8-ol Allopumiliotoxin 253a (8R,8aS,E)-6-((2R,6R,E)-6-Hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol Pumiliotoxin 309a (6E)-8-methyl-6-(2-methylhexylidene)-1,2,3,5,7,8a-hexahydroindolizine-7,8-diol (+)-Pumiliotoxin B 8-Methyl-6-(2-methylhexylidene)-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (1S,9aS,Z)-3-((2R)-6-Hydroxy-2,5-dimethyloctylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-6-((R)-7-Hydroxy-2-methylheptylidene)-8-methyloctahydroindolizin-8-ol (8S,8aS,Z)-6-((R,E)-2,5-Dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol (8S,8aS,Z)-8-Methyl-6-((R,E)-2-methyl-5-((4R,5S)-2,2,5-trimethyl-1,3,2-dioxasilolan-4-yl)hex-4-en-1-ylidene)octahydroindolizin-8-ol